Breaking News Instant updates and real-time market news.

MACK

Merrimack

$3.21

0.1 (3.22%)

, SHPG

Shire

$178.25

1.27 (0.72%)

10:24
03/16/17
03/16
10:24
03/16/17
10:24

Merrimack strength attributed to takeover specuation

Traders are attributing the move higher in shares of Merrimack Pharmaceuticals (MACK) to speculation of a takeover. The conjecture has Shire (SHPG) as the potential suitor. The Fly, in fulfilling its mission of explaining stock movement, often comes across the many unconfirmed rumors being passed through trading desks and social media platforms. On the occasion that rumors or speculation appear on The Fly's news feed, it should be viewed not as giving credence to the conjecture, rather as simply highlighting its impact on the stock prices of the companies involved. Shares of Merrimack are up 5%, or 17c, to $3.38 in morning trading.

MACK

Merrimack

$3.21

0.1 (3.22%)

SHPG

Shire

$178.25

1.27 (0.72%)

  • 01

    Apr

  • 26

    Jun

MACK Merrimack
$3.21

0.1 (3.22%)

08/19/16
BTIG
08/19/16
INITIATION
BTIG
Neutral
Merrimack initiated with a Neutral at BTIG
BTIG analyst Ling Wang initiated Merrimack with a Neutral as he expects shares to be range-bound given the likely slow ramp-up of ONIVYDE and data from MM-302 and MM-121 won't be available until 2017 or beyond;
10/07/16
JPMS
10/07/16
DOWNGRADE
Target $7
JPMS
Neutral
Merrimack downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Merrimack Pharmaceuticals to Neutral saying the shares are likely to be range-bound after rallying 36% from the 52-week low on September 20. Key pipeline catalysts aren't likely until Q2 of 2017 and beyond while 2016 estimates are not "meaningfully beatable," Rama tells investors in a research note. He lowered his price target for the shares to $7 from $8.
11/14/16
JPMS
11/14/16
NO CHANGE
JPMS
JPMorgan says Merrimack could fit as target for Shire
JPMorgan analyst Anupam Rama believes Merrimack Pharmaceuticals (MACK) could fit as a potential target for Shire (SHPG). The $1B deal size would be manageable, Rama tells investors in a research note after Ben Harrington's Betaville blog, citing sources, reported Friday that Shire is among the companies participating in Merrimack's strategic review process. Assuming a 40% premium to the intraday Merrimack share price, the deal would be 1% accretive in 2019 and 2% accretive in 2020, Rama estimates.
01/30/17
JANY
01/30/17
NO CHANGE
Target $44
JANY
Neutral
Clovis rally has taken stock up 'too far too fast,' says Janney Capital
Janney Capital analyst Debjit Chattopadhyay noted that Clovis (CLVS) shares are up about 41% year-to-date, citing accelerated approval for its rucaparib drug in advanced ovarian cancer, the all cash acquisition of Ariad (ARIA) and the $575M divestiture with potential for further payments of Merrimack's (MACK) Onivyde franchise as among the tailwinds driving Clovis shares higher. However, a "near-term Clovis buyout may not materialize" until key competitive readouts settle the debate on the equivalency/superiority of various PARP inhibitors, Chattopadhyay tells investors. Based on near-term uncertainties, he advises waiting for a better entry point to Clovis shares, on which he has a Neutral rating and $44 fair value estimate.
SHPG Shire
$178.25

1.27 (0.72%)

12/06/16
UBSW
12/06/16
DOWNGRADE
UBSW
Neutral
Shire downgraded to Neutral from Buy at UBS
01/19/17
01/19/17
NO CHANGE

Shire's application for ADHD disorder candidate acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. SHP465 is being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder. The FDA is expected to provide a decision on or around June 20. Shire resubmitted the NDA for SHP465 in response to the Approvable Letter from the FDA that requested additional clinical studies and classified the response as a Class 2 resubmission with a review goal of six months. Launch is planned for the second half of 2017.
03/07/17
LEHM
03/07/17
INITIATION
LEHM
Overweight
Shire reinstated with an Overweight at Barclays
After his firm dropped coverage in June 2016, Barclays analyst Emmanuel Papadakis reinstated Shire with an Overweight rating and GBP 65 price target. The rating is unchanged from last year.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
European Pharma raised to Positive from Neutral at Barclays
Barclays analyst Emmanuel Papadakis rolled out coverage of the European Pharmaceuticals space and upgraded his sector view to Positive from Neutral. The analyst has "high conviction that the recent transformational era of R&D innovation is set to continue," which he believes will allow the sector to retain pricing power. Papadakis put Overweight ratings on AstraZeneca (AZN), Roche (RHHBY) and Shire (SHPG), with Astra his top pick. The analyst put an Equal Weight rating on GlaxoSmithKline (GSK) and Underweight ratings on Sanofi (SNY), Novartis (NVS) and Novo Nordisk (NVO).

TODAY'S FREE FLY STORIES

CNX

Consol

$16.50

0.465 (2.90%)

14:30
11/17/17
11/17
14:30
11/17/17
14:30
Options
Far upside call buyer in CNX »

Far upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

, AMGN

Amgen

$170.77

1.39 (0.82%)

14:29
11/17/17
11/17
14:29
11/17/17
14:29
Periodicals
Xenon higher as CNBC's Tirrell reports on nonaddictive pain medicines »

Six drug companies are…

XENE

Xenon Pharmaceuticals

AMGN

Amgen

$170.77

1.39 (0.82%)

RHHBY

Roche

$28.90

0.165 (0.57%)

BIIB

Biogen

$313.98

3.7 (1.19%)

RGEN

Repligen

$33.73

1.12 (3.43%)

VRTX

Vertex

$147.94

-0.72 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 23

    Dec

  • 03

    Feb

  • 23

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

RIO

Rio Tinto

$47.70

0.065 (0.14%)

14:25
11/17/17
11/17
14:25
11/17/17
14:25
Periodicals
Rio Tinto working with advisers on bid for stake in SQM, Bloomberg says »

Rio Tinto has lined up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$23.69

-0.92 (-3.74%)

14:25
11/17/17
11/17
14:25
11/17/17
14:25
Options
Viacom call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
11/17/17
11/17
14:25
11/17/17
14:25
General news
Action Economics Survey results »

Action Economics Survey…

TWX

Time Warner

$88.79

0.7799 (0.89%)

, DIS

Disney

$103.63

0.03 (0.03%)

14:23
11/17/17
11/17
14:23
11/17/17
14:23
Periodicals
'Justice League' grosses roughly $16M in opening day in China, Forbes says »

Warner Bros. (TWX) latest…

TWX

Time Warner

$88.79

0.7799 (0.89%)

DIS

Disney

$103.63

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/17/17
11/17
14:17
11/17/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/17/17
11/17
14:16
11/17/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.77

-0.12 (-0.81%)

14:00
11/17/17
11/17
14:00
11/17/17
14:00
Conference/Events
Pan American Silver investor and analyst day »

Investor and Analyst Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TJX

TJX

$70.99

1.93 (2.79%)

14:00
11/17/17
11/17
14:00
11/17/17
14:00
Options
Notable options activity in TJX as shares see strength »

Notable options activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFSW

PFSweb

$6.80

0.21 (3.19%)

13:59
11/17/17
11/17
13:59
11/17/17
13:59
Hot Stocks
PFSweb rallies after Ancora discloses activist stake »

Ancora Advisors earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$103.86

-0.95 (-0.91%)

13:52
11/17/17
11/17
13:52
11/17/17
13:52
Recommendations
RH analyst commentary  »

RH price target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$38.49

1.76 (4.79%)

13:45
11/17/17
11/17
13:45
11/17/17
13:45
Options
Hain Celestial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEG

PSEG

$51.40

0.015 (0.03%)

13:36
11/17/17
11/17
13:36
11/17/17
13:36
Syndicate
Breaking Syndicate news story on PSEG »

PSEG files $129.1M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$89.05

-0.64 (-0.71%)

13:33
11/17/17
11/17
13:33
11/17/17
13:33
Hot Stocks
Indiana American Water acquires Georgetown Water System for about $6.4M »

Indiana American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COT

Cott Corp.

$16.86

0.36 (2.18%)

13:30
11/17/17
11/17
13:30
11/17/17
13:30
Options
Cott Corp call buying continues »

Cott Corp call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
11/17/17
11/17
13:30
11/17/17
13:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

CC

Chemours

$52.23

0.705 (1.37%)

13:27
11/17/17
11/17
13:27
11/17/17
13:27
Periodicals
Chemours tells Bloomberg N.C. permit revocation 'unwarranted' »

The comment was issued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

13:25
11/17/17
11/17
13:25
11/17/17
13:25
General news
An exodus from U.S. high yield debt this week »

An exodus from U.S. high…

STBZ

State Bank Financial

$28.69

0.21 (0.74%)

13:25
11/17/17
11/17
13:25
11/17/17
13:25
Conference/Events
State Bank Financial participates in a conference call with SunTrust »

Suntrust Bank Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

HIBB

Hibbett Sports

$14.85

0.8 (5.69%)

13:24
11/17/17
11/17
13:24
11/17/17
13:24
Recommendations
Hibbett Sports analyst commentary  »

Hibbett Sports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

FL

Foot Locker

$40.18

8.33 (26.15%)

13:23
11/17/17
11/17
13:23
11/17/17
13:23
Recommendations
Foot Locker analyst commentary  »

Foot Locker quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

MS

Morgan Stanley

$48.67

0.065 (0.13%)

13:20
11/17/17
11/17
13:20
11/17/17
13:20
Options
Morgan Stanley calls lead puts 9:1 »

Morgan Stanley calls lead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
11/17/17
11/17
13:17
11/17/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/17/17
11/17
13:16
11/17/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.